CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated

CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated

KING OF PRUSSIA, Pa — 18/11/2014

Two New Research Studies Provide Further Support for the Potential Role of CSL112 in the Reduction of Early Recurrent Cardiovascular Events following Myocardial Infarction

Two research studies presented today at the American Heart Association Scientific Sessions in Chicago provide further understanding of the mechanisms by which CSL112, a novel formulation of apolipoprotein A-1 (apoA-1), may reduce the high incidence of early recurrent cardiovascular events seen in post MI patients. Early recurrent cardiovascular events are associated with high morbidity and mortality, and reducing early events is an important target for new therapies.


Read the full release:
CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated


For further information, please contact:


Investors:
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 2818
  Email: mark.dehring@csl.com.au
Media:
  Sharon McHale
  Senior Director Public Affairs
  CSL Limited
  Mobile: +61 409 978 314
  Email: sharon.mchale@csl.com.au

© 2017 CSL Limited